PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal use of antibiotics in the emergency department (PRONTO): protocol for a multicentre, open-label, randomised controlled trial. Issue 6 (13th June 2022)

• Record Type: Journal Article
• Authors: Euden, Joanne; Thomas-Jones, Emma; Aston, Stephen; Brookes-Howell, Lucy; Carman, Julie; Carrol, Enitan; Gilbert, Stephanie; Howard, Philip; Hood, Kerenza; Inada-Kim, Matthew; Llewelyn, Martin; McGill, Fiona; Milosevic, Sarah; Niessen, Louis Wihelmus; Nsutebu, Emmanuel; Pallmann, Philip; Schmidt, Paul; Taylor-Robinson, David; Welters, Ingeborg; Todd, Stacy; French, Neil
• Other Names: author non-byline.; Clarkstone Sam author non-byline.; Hughes Jacqui author non-byline.; Meister Lena author non-byline.; Tabner Andrew author non-byline.; Barlow Gavin author non-byline.; Body Richard author non-byline.; Bradburn Mike author non-byline.; Daniels Jane author non-byline.; Richards Emma author non-byline.; Brain Angela author non-byline.; Walker Sarah author non-byline.; Goodacre Steve author non-byline.; Scarborough Matthew author non-byline.; O'Shea Sian author non-byline.; James Claire author non-byline.
• Is Part Of: BMJ open. Volume 12:Issue 6(2022)
• Publication Date: 2022-06-13
• Subjects: accident & emergency medicine -- infection control -- adult intensive & critical care; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-063424
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Sepsis is a common, potentially life-threatening complication of infection. The optimal treatment for sepsis includes prompt antibiotics and intravenous fluids, facilitated by its early and accurate recognition. Currently, clinicians identify and assess severity of suspected sepsis using validated clinical scoring systems. In England, the National Early Warning Score 2 (NEWS2) has been mandated across all National Health Service (NHS) trusts and ambulance organisations. Like many clinical scoring systems, NEWS2 should not be used without clinical judgement to determine either the level of acuity or a diagnosis. Despite this, there is a tendency to overemphasise the score in isolation in patients with suspected infection, leading to the overprescription of antibiotics and potentially treatment-related complications and rising antimicrobial resistance. The biomarker procalcitonin (PCT) has been shown to be useful in specific circumstances to support appropriate antibiotics prescribing by identifying bacterial infection. PCT is not routinely used in the care of undifferentiated patients presenting to emergency departments (EDs), and the evidence base of its optimal usage is poor. The PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal (PRONTO) study is a randomised controlled trial (RCT) in adults with suspected sepsis presenting to the ED to compare standard clinical management based on NEWS2 scoring plus PCT-guided risk assessment with standard clinical management based on NEWS2 scoring alone and compare if this approach reduces prescriptions of antibiotics without increasing mortality. Methods and analysis: PRONTO is a parallel two-arm open-label individually RCT set in up to 20 NHS EDs in the UK with a target sample size of 7676 participants. Participants will be randomised in a ratio of 1:1 to standard clinical management based on NEWS2 scoring or standard clinical management based on NEWS2 scoring plus PCT-guided risk assessment. We will compare whether the addition of PCT measurement to NEWS2 scoring can lead to a reduction in intravenous antibiotic initiation in ED patients managed as suspected sepsis, with at least no increase in 28-day mortality compared with NEWS2 scoring alone (in conjunction with local standard care pathways). PRONTO has two coprimary endpoints: initiation of intravenous antibiotics at 3 hours (superiority comparison) and 28-day mortality (non-inferiority comparison). The study has an internal pilot phase and group-sequential stopping rules for effectiveness and futility/safety, as well as a qualitative substudy and a health economic evaluation. Ethics and dissemination: The trial protocol was approved by the Health Research Authority (HRA) and NHS Research Ethics Committee (Wales REC 2, reference 20/WA/0058). In England and Wales, the law allows the use of deferred consent in approved research situations (including ED studies) where the time dependent nature of intervention would not allow true informed consent to be obtained. PRONTO has approval for a deferred consent process to be used. Findings will be disseminated through peer-reviewed journals and presented at scientific conferences. Trial registration number: ISRCTN54006056 .